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EXPRESSION OF  INTERLEUKIN  2 RECEPTORS 
ON ACT IVATED HUMAN B CELLS 
BY THOMAS A. WALDMANN, CAROLYN K. GOLDMAN, RICHARD J. ROBB, 
JOEL M. DEPPER, WARREN J. LEONARD, SUSAN O. SHARROW, 
KATHLEEN F. BONGIOVANNI, STANLEY J. KORSMEYER, ANn 
WARNER C. GREENE 
From the Metabolism Branch and Immunology Branch, National Cancer Institute, National 
Institutes of Health, Bethesda, Maryland 20205; and the Central Research Division, E. L 
du Pont de Nemours and Company, Glenolden Laboratory, Glenolden, Pennsylvania 19036 
Several antigen-nonspecific, genetically unrestricted factors derived from T 
cells have been shown to play a role in the regulation of B cell responses (1-9). 
One such factor, designated B cell growth factor (BCGF-1 or BSF-1), ~ appears 
to be required for the proliferation of a subset of B cells after interaction with 
antigen or antiimmunoglobulin molecules. A second series of factors, called B 
cell differentiation (BCDF) or T cell-replacing factors (TRF), is involved in the 
terminal maturation of proliferating B cells into immunoglobulin-secreting cells. 
There has been controversy regarding the possible involvement of T cell growth 
factor or interleukin 2 (IL-2) in B cell responses and specifically the ability of 
this growth factor to act directly on B lymphocytes. The proponents of a direct 
action of IL-2 on B cells showed that depletion of IL-2 from cofactor-rich 
supernatants by absorption on IL-2-dependent T cell lines also removed a factor 
required for B cell differentiation (4, 5, 10). Furthermore, there was a strict 
correlation between the levels of IL-2 and one of the B cell-specific factors 
required for antibody production (4). This view that IL-2 acts directly on B cells 
has been challenged, since both mouse and human IL-2 have been distinguished 
from B cell growth and differentiation factors (7-11). The IL-2-containing 
supernatants generally used in the previous tudies (the supernatant of the FS6- 
14.13 line) also contained BCGF and one or more TRFs (9). Furthermore, IL-2 
was not absorbed from cofactor-rich supernatants by incubation with lipopoly- 
saccharide (LPS)-stimulated splenic lymphoblasts (4). Finally, radiolabeled IL-2 
did not bind to LPS-stimulated B cells or to either of the two Burkitt's lymphoma 
B cell lines examined (Raji and Daudi) suggesting that B cells do not manifest 
receptors for IL-2 (12). 
We have reexplored the possibility that certain activated B cells display recep- 
tors for IL-2 using the anti-Tac monoclonal antibody produced in our laboratory 
(13, 14). This monoclonal antibody identifies the human membrane receptor for 
IL-2 (15, 16, 17). The observations that led to this conclusion include: (a) anti- 
Abbreviations used in this paper: BCDF, B cell differentiation factor; BCGF, B cell growth factor; 
EBV, Epstein-Barr virus; IL-2, interleukin 2; LPS, lipopolysaccharide; NWSM, Nocardia water- 
soluble mitogen; PWM, pokeweed mitogen; SDS, sodium dodecyl sulfate; SLO, Streptolysin-O; 
WGA, wheat germ agglutinin. 
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Tac blocks the proliferation of IL-2-dependent T cell lines, but does not affect 
the proliferation of IL-2-independent T cell lines; (b) anti-Tac blocks the binding 
of radiolabeled IL-2 to its specific receptor on activated T cells; and (c) IL-2 
blocks the binding of radiolabeled anti-Tac to its antigenic target on activated T
cells and T cell lines. Furthermore, all membrane-associated, IL-2-binding mol- 
ecules were removed by passage through an anti-Tac Sepharose column and, in 
parallel studies, all molecules that bound to an anti-Tac Sepharose column were 
removed by prior passage through an IL-2 Affigel affinity support (16). Thus, 
under the conditions examined, all anti-Tac-reactive molecules appeared capable 
of binding IL-2 and the ability to bind IL-2 was limited to the Tac protein. 
Previously (17, 18), we made two observations using the monoclonal anti-Tac 
that suggested that IL-2 might play a role in B cell maturation. First, anti-Tac 
inhibited the maturation of B cells into immunoglobulin-secreting cells as mea- 
sured in a reverse hemolytic plaque assay when peripheral blood mononuclear 
cells were stimulated with pokeweed mitogen (PWM) (17). Secondly, virtually all 
hairy cell leukemic populations that were demonstrated tobe B cells on the basis 
of immunoglobulin gene rearrangements displayed the Tac antigen on the cell 
surface (18). 
In the present study we demonstrate hat, while normal resting B cells are Tac 
antigen negative, these cells can be activated to express the Tac antigen. Fur- 
thermore, we demonstrate that certain leukemic B cell populations are Tac 
antigen positive. In addition, cloned lines of normal, Epstein-Barr virus (EBV)- 
transformed B cells display the Tac antigen and high affinity IL-2 receptors 
detected with radiolabeled IL-2. We also demonstrate hat the receptor identified 
by anti-Tac on activated B cells is similar in size (Mr 55,000) to the IL-2 receptor 
present on activated T cells. Finally using a Tac-positive cloned normal B cell 
line, we demonstrate hat purified IL-2 is capable of amplifying the level of Tac 
antigen expression and inducing augmented immunoglobulin production. Thus, 
IL-2 receptor expression does not appear to be confined to cells of the T cell 
lineage, but can also be induced on normal B lymphocytes. 
Materials and Methods 
Cells Analyzed for IL-2 Receptor Expression. Purified B cells prepared from heparinized 
peripheral blood from five normal individuals and EBV-transformed B cell lines from six 
normal individuals, from six patients with adult T cell leukemia, and from 10 patients 
with Burkitt's lymphoma were analyzed for surface IL-2 receptor expression by indirect 
immunofluorescent staining with anti-Tac. The purified B cells were prepared from 
normal, heparinized venous blood using Ficoli-Hypaque (Pharmacia Fine Chemicals, 
Piscataway, NJ) density gradient centrifugation to isolate mononuclear cells, followed by 
centrifugal elutriation to remove monocytes. The T cells were removed from these 
lymphocyte preparations by rosette formation with neuraminidase-treated sheep eryth- 
rocytes. The Burkitt's lymphoma lines were established from the involved lymph nodes 
of patients with the clinical features of Burkitt's lymphoma. Each of the lines demonstrated 
the reciprocal translocation between chromosome 8 and chromosomes 14, 2, or 22 
characteristic of Burkitt's lymphoma. The adult T cell leukemia patients had circulating 
antibodies to the p19 and p24 structural (gag) proteins of human T cell leukemia/ 
lymphoma virus [ (HTLV-I) (19). Four of the five B cell lines examined from these 
patients contained HTLV-I provirus integrated into thei r genome as identified by molec- 
ular hybridization studies. The EBV-transformed, B cell lines were established from 
normal individuals using heparinized peripheral blood mononuclear cells depleted of T 
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cells by rosetting with neuraminidase-treated sheep erythrocytes and transformed with 
EBV (culture supernatant of line B95-8). These B cell preparations contained <4% T 
cells as defined by flow microfluorometry after staining with Leu-4 (pan T ceil) monoclonal 
antibody. 
To induce Tac antigen expression in these freshly obtained normal purified B cells 
prepared as described above, 1 x 106 purified B cells were co-cultured with 1 X 105 
irradiated (2,000 rad) T cells and 1 X 104 irradiated (10,000 rad) monocytes in the 
presence of PWM (10 #g) for 6 d in RPMI 1640 media supplemented with 10% fetal calf 
serum. At the end of the culture period, the T cells were removed by rosetting with 
neuraminidase-treated sheep erythrocytes, and the residual B cells were assessed by flow 
microfluorometry for reactivity with Leu-4, Leu-10, and anti-Tac monoclonal ntibodies. 
To establish Tac-positive B cell lines from normal individuals, B cells activated by the 
procedure described above were incubated with anti-Tac for 30 min and then rosetted in 
the presence of ox erythrocytes coated with an anti-mouse immunoglobulin reagent. Cells 
rosetted in this manner were separated from the nonrosetting cells by Ficoil-Hypaque 
centrifugation a d then cultured in RPMI 1640 media supplemented with 20% fetal calf 
serum in the presence of EBV (B95-8 supernatant) for 4 wk. The resulting lines were 
then reassessed for reactivity with anti-Tac. A line (designated B22) demonstrating 25% 
reactivity with anti-Tac was cloned by limiting dilution at a density of 0.5 B cells/well in 
96-well, round-bottom Costar plates in the presence of 2 x 104 allogeneic, irradiated 
(5,000 rad) peripheral blood lymphocytes a  a feeder layer. Two clones, 1C9 and 5B4, 
were expanded for more extensive analysis. Both clones secreted immunoglobulin; clone 
1 C9 produced IgG~ while 5B4 produced IgMK. 
Monoelonal Antibodies. The OKT3, T4, T8, T9, and T10 antibodies were obtained 
from Ortho Diagnostic Systems Inc., Westwood, MA. The Leu-4 and Leu-10 antibodies 
were obtained from Becton, Dickinson & Co., Mountain View, CA. The B1 and fluores- 
cein-conjugated F(ab')2 goat anti-mouse immunoglobulin antibodies were obtained from 
Coulter Electronics, Hialeah, FL. 
The preparation of the murine hybridoma-producing monoclonal anti-Tac antibody, 
an anti-I L-2 receptor antibody, has been previously described (13-15). In this study, anti- 
Tac antibody used in in vitro immunoglobulin biosynthesis experiments was purified from 
mouse ascites by DEAE cellulose (Whatman Laboratory Products, Inc., Clifton, NJ) ion 
exchange chromatography using gradient elution in Tris buffer, pH 8.0, ranging in 
molarity from 0.01 to 0.3 M. Anti-Tac antibody conjugated for fluorescence studies was 
purified from ascites by affinity chromatography with staphylococcal protein A-Sepharose 
(Pharmacia Fine Chemicals) according to the method of Ey et al. (20). The purified 
antibody was conjugated to biotin succinamide (Bioresearch, San Rafael, CA). Avidin 
(Pierce Chemical Co., Rockford, IL) was conjugated to fluorescein isotbiocyanate (Sigma 
Chemical Co., St. Louis, MO) using the method of Rinderknecht (21) or to Texas Red 
(Molecular Probes, Junction City, OR) using the method of Titus et al. (22). 
Iramunofluorescence Staining. The cells were analyzed using immunofluorescence and 
flow microfluorometry analyses by a modification of a procedure previously described 
(23). Cell suspensions for immunofluorescent staining were prepared in Hanks' balanced 
salt solution (without phenol red) containing 3% fetal calf serum and 0.05% sodium azide. 
For indirect one-color staining, 1 x 106 cells were incubated for 30 min at 4°C with 
saturating amounts of the appropriate monoclonal ntibody or mouse serum as a control, 
washed twice, incubated 30 min at 4°C with fluorescein-conjugated anti-mouse immuno- 
globulin reagent, rewashed twice, and finally resuspended and analyzed for fluorescence. 
For dual fluorescence studies, cells were stained initially with biotin-conjugated anti-Tac 
antibody followed by Texas Red-conjugated avidin and then stained with fluorescein- 
conjugated antibody with appropriate washing between incubations. 
For inhibition experiments, 1 x 106 cells were incubated for 60 rain at 4°C with the 
material being tested for blocking activity. Either fluorescein-conjugated antibody or 
biotin-conjugated anti-Tac antibody were then added directly to the cells with no inter- 
vening washing and incubated for 20 min at 4°C. Suspensions were then washed twice 
and analyzed for fluorescence or further incubated with Texas Red or fluorescein- 
WALDMANN ET AL. 1453 
conjugated avidin before analysis as indicated. Flow microfluorometry analyses were 
performed using a Dual Laser FACS II (B-D FACS Systems, Sunnyvale, CA) and data 
were collected and analyzed using a PDP 11/34 computer (Digital Equipment Corp., 
Maynard, MA) interfaced to the FACS II. Fluorescence data were collected using loga- 
rithmic amplification on 5 × 104 viable cells as determined by forward light scatter 
intensity. Data from inhibition experiments were calculated as previously described (23). 
Source of lnterleukin 2 and Polyctonal Activators. Two preparations of IL-2, immunoaf- 
finity-purified, JURKAT-derived IL-2 and recombinant IL-2, were used in the present 
study to assure that I L-2 itself rather than any potential contaminant was the active agent. 
The procedures used to purify and characterize the JURKAT-derived IL-2 have been 
described previously (24). The IL-2 was prepared by column affinity chromatography 
using an I L-2-binding monoclonal antibody, 1 H 11-1 AS, immobilized on Sepharose 4B. 
The bound IL-2 was eluted with 1.5% acetic acid, pH 2.5. When analyzed by two- 
dimensional gel electrophoresis u ing silver staining for detection, the contents of the pH 
2.5 eluate migrated as a single spot. The recombinant-purified IL-2 was obtained from 
Cetus Corp., Emeryville, CA from the JURKAT IL-2 gene expressed in E. coli (25). The 
protein was 96% pure by SDS-PAGE analysis and contained <0.3 ng of LPS/1,000,000 
U of IL-2 as assessed by the limulus amebocyte assay. The IL-2 concentrations u ed in 
the present study are expressed as nanograms per milliliter. There are 0.31 U/ng of IL- 
2, where the units are those described previously by Robb and co-workers (24). One such 
unit of IL-2 activity is equivalent to 41.5 U as recently defined by the Biological Response 
Modifiers program of the National Cancer Institute. 
A series of materials were used in the in vitro studies to activate B lymphocytes to 
synthesize and secrete immunoglobulin molecules. PWM was obtained from Gibco Lab- 
oratories, Grand Island, NY. Nocardia water-soluble mitogen (NWSM) was the kind girl 
of Dr. Constantin Bona. Wheat germ agglutinin (WGA) was obtained from Miles Labo- 
ratories, Elkhart, IN. Streptolysin-O (SLO) was obtained from Difco Laboratories, Detroit, 
MI. 
Measurement of lmmunoglobulin Synthesis by Lymphocytes Cultured In Vitro. To study the 
effect of the anti-Tac monoclonal ntibody on the differentiation fcirculating B lympho- 
cytes into immunoglobulin-synthesizing and -secreting cells, normal peripheral blood B 
cells and monocytes free of T cells were co-cultured with autologous, irradiated (2,000 
rad) T cells. Polyclonal activators were added in the presence of anti-Tac or a control 
monoclonal immunoglobulin (RPC-5; Litton Bionetics, Inc., Kensington, MD) of the same 
IgG2a isotype. The B cell and T cell populations for these studies were extensively washed 
to remove serum immunoglobulins and then prepared according to techniques described 
previously (26) using a two-step procedure that involves passage of peripheral blood 
mononuclear cells through an anti-human F(ab')~ immunoabsorbent column followed by 
a rosetting step with neuramhaidase-treated sh ep erythrocytes. In the biosynthesis exper- 
iment 1 x 10~B cells and 1 x 106 irradiated (2,000 rad) T cells were co-cultured in the 
presence of optimal concentrations of PWM, WGA, SLO, or NWSM (26) for 12 d in 
RPMI 1640 media supplemented with 10% fetal calf serum (Armour Pharmaceutical Co., 
Phoenix, AZ), 2 mM L-glutamine (Gibco Laboratories), and 50 #g/mi penicillin and 
streptomycin solution (Gibco Laboratories). 
Scatchard Analysis of 3H-Anti-Tac Binding to Tac-positive B Cell Lines. To estimate 
receptor number and ligand affinity, purified anti-Tac was tritiated to high specific activity 
by reductive methylation (910 Ci/mmol) (27). Cell populations to be examined were 
washed three to four times in balanced salt solution and suspended at 20 x 108 viable 
cells/ml in binding medium [RPMI 1640, 1% bovine serum albumin (Sigma Chemical 
Co.), 1 mg/ml human IgG (Cutter), 25 mM Hepes (Gibco Laboratories), and 0.1% sodium 
azide (Sigma Chemical Co.)]. Aliquots of 106 cells were incubated with labeled antibody 
(1-11 ng, depending on the assay) for 45 rain at room temperature in the presence of 
graded amounts (0-1,600 ng) of unlabeled anti-Tac in a final volume of 90-200 #1 in 1.5- 
ml Eppendorf tubes. Cell-associated and free radiolabeled antibodies were separated by 
centrifuging the reaction mixture through 750-t~1 cushions of binding medium containing 
1 M sucrose. Supernatants were aspirated and the cell pellets resuspended in balanced 
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salt solution and tranferred to glass vials for liquid scintillation counting. Specific binding 
was determined by incubating cells and labeled antibody with a >l,000-fold excess of 
unlabeled anti-Tac, generally 28 #g. Scatchard analyses (28, 29) were performed by 
plotting the values for bound/free vs. bound radioactivity. 
Radiolabeted IL-2-binding Assay. Biosynthetically radiolabeled human IL-2 was pre- 
pared by stimulation of JURKAT cells (4 × 106/ml) in serum-free Dulbecco's modified 
Eagle's medium containing 40 #M unlabeled leucine, 65 #M unlabeled lysine, 0.5 mCi/ 
ml of [3H]leucine (52 Ci/mmol; ICN Nutritional Biochemicals, Cleveland, OH), 0.5 mCi/ 
ml [3H]lysine (39 Ci/mmol), 1.5 #g/ml phytohemagglutinin (HA-16; Weilcome Reagents), 
and 50 ng/ml phorboi-12-myristic-13-acetate (Consolidated Midlands Corp.) (12). After 
16 h at 37 ° C, the cell supernatant was harvested and the radiolabeled I L-2 was extracted 
by immunoaffinity chromatography (24). The labeled IL-2 (23 x 106 dpm/#g) migrated 
as a single band at 15,500 Mr on SDS-PAGE. 
The level and affinity of [~H]IL-2 binding to cells was determined as previously 
described (12) by incubating a known quantity of cells (0.5 to 1.5 x 106) with serial 
dilutions of [SH]IL-2 in RPMI 1640, I0 mg]ml bovine serum albumin, 25 mM Hepes, 
pH 7.2 (RPMI-BSA), in a final volume of 0.1 ml. After 20 min at 37°C, the cells were 
washed twice with ice-cold RPMI-BSA and centrifuged through a 400-#1 layer of 85% 
silicon oil/15% paraffin oil. The tip of the tube containing the cell pellet was transferred 
to a scintillation vial where the cells were suspended in 200 #1 PBS, then lysed and 
dissolved by the addition of 200 #1 1% SDS. 
Structure of Receptor on B Cells Identified by Anti-Tac. 10-20 x 106 cells were incubated 
and biosynthetically abeled for 18 b with 250-500 #Ci of [~H]D-glucosamine (32.5 Ci/ 
mmol; New England Nuclear, Boston, MA). Cells were then washed and solubilized for 
30-60 rain at 4°C in 0.14 M NaCI, 1% Triton X-100, 10 mM Tris HCI (pH 7.4), and 50 
#g/ml phenylmethylsulfonyl fluoride. Nuclei and cell debris were removed by centrifuga- 
tion (12,000 g for 15 min) and the supernatants immunoprecipitated with anti-Tac and 
Cowan I strain staphylococci aspreviously described (15, 30). Immunoprecipitates were 
analyzed by 8.75% SDS-PAGE performed under educing conditions. Gels were enhanced 
(Enlightning; New England Nuclear), dried under vacuum, and analyzed after fluorog- 
raphy. In parallel studies, surface proteins of the B cell lines were labeled by lactoperoxi- 
dase-catalyzed iodination. ~5-10 x 106 cells were washed and suspended in 100 #1 of 
balanced salt solution and 1 mCi of carrier-free Nal~SI was added. 4 #1 of lactoperoxidase 
solution (100 U/ml) and 7.5 #1 of H202 solution (0.03%) were then added and the cells 
incubated for 4 min at room temperature. An additional 2 #1 of lactoperoxidase solution 
and 7.5 #i of H~O2 were then added and cells incubated for an additional 4 min. Cells 
were then washed in balanced salt solution and immunoprecipitated as escribed above. 
Results 
Anti-Tac Inhibits Helper T Cell-dependent Immunoglobulin Synthesis. The ability 
of  anti-Tac to inhibit helper T cel l -dependent immunoglobulin synthesis by 
normal B cells was evaluated using an in vitro biosynthesis system. B cells and 
irradiated (2,000 rad) T cells isolated from normal individuals were combined 
and cultured at 5 X 105 cells/ml for 12 d with PWM, WGA, SLO, or NWSM. 
The  immunoglobulins synthesized and secreted into the media during the 12-d 
culture period were assayed using sensitive double antibody radioimmunoassays 
for IgM, IgG, and IgA (31, 32). The  geometric mean values for IgM synthesis 
by B and T cells from 10 normal individuals after stimulation for 12 d with 
PWM, WGA, SLO, and NWSM were 4,180 (1.4) ~ ng, 7,950 (2.5) ng, 7,612 (1.6) 
ng, and 3,879 (1.5) ng, respectively, per 10 6 cells in 1-mi cultures. Purified anti- 
Tac, when added at a final concentration of  2 #g/ml, inhibited IgM synthesis by 
57, 64, 47, and 53% for cultures timulated by PWM, WGA, SLO, and NWSM, 
2 Standard error of the log of geometric mean. 
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respectively (Fig. 1). Anti-Tac also comparably inhibited IgG and IgA synthesis 
(data not shown). A control monoclonal antibody (RPC-5) of the same isotype 
(IgG2a) as anti-Tac did not inhibit the immunoglobulin synthesis induced by 
these stimulants (Fig. 1). The suppression of immunoglobulin biosynthesis by 2 
t~g of anti-Tac was overcome by the addition of 50 ng of purified JURKAT- 
derived I L-2 to the biosynthesis system, supporting the view that anti-Tac inhibits 
through binding to the IL-2 receptor. However, the maturation of B cells to 
immunoglobulin-synthesizing cellsrequires the participation of helper T cells 
with the polyclonal activators used (32). Thus, the site of action of anti-Tac in 
this system cannot be completely defined; both an effect on T cells to inhibit 
their secretion of B cell growth and differentiation factors or a direct action at 
the B cell level are possible. 
Interleukin 2 Receptors on B Cells. For anti-Tac to act directly on B cells, the 
B cells would be expected to display the Tac antigen (i.e., IL-2 receptors). To 
determine whether B cells manifest IL-2 receptors, purified B cells from five 
normal individuals and from individuals with B cell leukemias were examined by 
indirect immunofluorescence using anti-Tac. Anti-Tac did not react with rigor- 
ously purified resting normal B cells (Fig. 2). Furthermore, five of six unselected 
B cell lines from normal individuals, established using EBV, were Tac antigen 
negative. In contrast, the Tac antigen was demonstrable on the cell surface of 6 
of 10 B cell lines derived from patients with Burkitt's lymphoma nd on 5 of 6 
EBV-transformed B cell lines from patients with human T cell leukemia/lym- 
100 
~0 ~ 2/~1 of Purified Anti-TAC 
! f~g of ~1 Monoclon 
70 RPC-5 
o 
PWM WGA SLO NWSM 
2 vg  Control al 
FIGURE 1. Effects of the addition of monoclonal anti-Tac or control monoclonal RPC-5 
antibodies on ]gM synthesis and secretion of cultured normal B and irradiated (2,000 rad) T 
cells stimulated by pokeweed mitogen (PWM), wheat germ agglutinin (WGA), streptolysin-O 
(SLO), and Nocardia water-soluble mitogen (NWSM). Purified anti-Tac, when added at a final 
concentration of 2 izg/ml, inhibited polyclonal IgM synthesis by 47-64%, whereas control 
RPC-5 monoclona[ antibody did not inhibit immunoglobulin synthesis. 
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FIGURE 2. Activated B cells from patients with certain lymphoid malignancies manifest IL-2 
receptors identified by the anti-Tac monoclonal antibody. The percent of Tac-positive B cells 
are plotted for individuals with different disease states. The purified B cell populations were 
analyzed by indirect immunofluorescence flow microfluorometric analysis with anti-Tac and 
fluorescein-conjugated anti-mouse antibody reagents. 
phoma virus-associated a ult T cell leukemia. None of the B cell populations 
exhibiting anti-Tac reactivity by indirect fluorescence were reactive with the 
control monoclonal RPC-5 antibody or with the Leu-4 antibody, which reacts 
with virtually all mature T cells. 
Although normal resting B cells and the majority of unselected EBV-trans- 
formed B cell lines from normal individuals were Tac antigen negative, we next 
demonstrated that Tac antigen expression can be induced with normal B cells. 
Furthermore, we have successfully established cloned normal B cell lines that 
express Tac antigen. Populations of 1 × 106 purified B cells from normal 
individuals and 1 x 105 autologous (irradiated at 2,000 rad) T cells and 1 x 104 
irradiated (1,000 rad) monocytes were stimulated with PWM for 6 d. At the end 
of the culture period the T lymphocytes were removed by a neuraminidase heep 
erythrocyte rosetting procedure. The residual population of B lymphocytes were 
Leu-4 negative, Leu-10 positive, yet contained a proportion (21-43%) of Tac- 
positive cells, as evaluated by indirect immunofluorescence. Thus, normal pri- 
mary B cells could be induced to display the Tac antigen after PWM activation 
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in the presence of T cells. To establish Tac-positive B cell lines, the activated B
cells were incubated with the anti-Tac monoclonal antibody and then rosetted 
in the presence of ox erythrocytes coated with an antibody to mouse immuno- 
globulin. Rosetted Tac-positive B cells were cultured in the presence of EBV for 
4 wk. 5-39% of the cells in 9 of the 10 EBV-transformed B cell lines established 
by this method were Tac positive. Cloned lines were established from one of the 
Tac-positive B cell lines, B22, by limiting dilution at a density of 0.5 B cells/well. 
Two of the cloned lines, 1 C9, which constitutively expressed the Tac antigen, 
and 5B4, which could be induced to express Tac antigen, were further studied. 
Both the original line B22 and the cloned daughter lines 1C9 and induced 5B4 
contained a proportion of Tac-positive cells identified by microfluorometric 
analysis when they were stained with biotinylated anti-Tac and then incubated 
with fluoresceinated avidin. The cloned lines were not reactive with the mono- 
cional antibodies Leu-4, T4, T8, 3A-l, and T-11, which react with T cells. 
Furthermore, the Tac-positive cells also displayed surface immunoglobulin and 
the Leu-10 antigen characteristic of B cells when assessed by two-color fluores- 
cence studies. The addition of 500 ng of purified IL-2, derived from induced 
JURKAT leukemic cells, blocked the binding of anti-Tac to these lines (Table 
I). In contrast, the addition of 5,000 ng of IgM to the incubation system did not 
block the binding of anti-Tac to its receptor on line B22 although it blocked the 
binding of fluoresceinated anti-IgM to this line (Table I). 
The binding of 3H-anti-Tac to line 1 C9 was examined by Scatchard analysis 
as shown in Fig. 3. Approximately 7.4 × 10 s antibody molecules were bound per 
cell with an apparent Kd of 1.04 × 10 -l° M. In parallel studies using biosynthet- 
ically labeled IL-2 ( JURKAT), line 1 C9 expressed -1,400 high affinity (Kd, 2.7 
× 10 -1~ M) IL-2 binding sites per cell (average for the entire population in six 
experiments). Furthermore, binding of the [3H]IL-2 to 1C9 cells was inhibited 
by the anti-Tac antibody, demonstrating that, as on activated T cells, the IL-2- 
binding sites contain the Tac protein. These findings support he conclusion that 
normal B cells can be activated to express receptors for IL-2. 
Induction of lL-2 Receptors on a Normal B Cell Line by IL-2. The cloned normal 
B cell line 5B4 prepared as described above manifested only small numbers of 
cell surface molecules identified by anti-Tac. 5% of these cells were Tac positive 
by flow microfluorometry and displayed only 520 Tac molecules per cell (average 
for the entire population) as determined by Scatchard analysis of 3H-anti-Tac 
TABLE I 
Inhibition of Binding of Anti-Tac on the B Cell Line, B22, by Purified 
JURKAT IL-2 Assessed by Flow Cytometry 
Inhibitor added Inhibition of Inhibition f 
anti-Tac binding anti-human IgM 
binding 
% % 
IL-2 (500 ng) 100 7 
IL-2 (50 ng) 47 8 
IL-2 (5 ng) 38 14 
Human IgM (5,000 ng) 15 97 
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FIGURE 3. Scatchard analysis of SH-anti-Tac binding to a cloned normal B cell line. SH-anti- 
Tac binding was performed as described in the Materials and Methods ection. Transformation 
of binding data indicated that 1 C9 cells displayed ~7,400 receptors per cell with an apparent 
Ka of 1.04 x 10 -'° M. 
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LOGlo FLUORESCENCE INTENSITY 
FIGURE 4. Purified IL-2 induces augmented IL-2 receptor expression in cloned normal B 
cell line 5B4. Binding of anti-Tac or RPC-5 was measured by flow microfluorometry analysis 
of fluorescence intensity generated by reacting different cell populations with antibody 
conjugated to biotin succinimide and subsequently with avidin conjugated to fluorescein 
isothiocyanate. Before flow microfluorometric analysis induced 5B4 cells bad been incubated 
for 48 h with 50 ng/ml of immunoaffinity-purifiedJURKAT IL-2. 
binding. The ability of this population to be induced to express larger numbers 
of Tac receptors was explored after an initial observation that exposure of this 
line for 48 h to iectin-depleted conditioned medium containing IL-2 led to an 
increase in the proportion of Tac-positive cells from 5 to >30%. The addition 
of either immunoaffinity-purified JURKAT IL-2 or recombinant IL-2 to the 
culture in the range of 10-100 ng/106 cells increased the receptor number from 
520 to 4,500 per cell after 48 h of culture (Figs. 4-6). The addition of 1 ng/ml 
purified JURKAT IL-2 led to an intermediate 50% increase in the number of 
receptors per cells. This concentration (6 x 10 -ll M) required for one-half- 
maximal induction is comparable to the Kd (2.7 X 10 -~ M) for binding of 
[3H]IL-2 to ks receptor on the cloned B cell line. An increase in specific binding 
was seen as early as 12 h after exposure to the purifiedJURKAT IL-2 preparation 
and reached a maximum at 48 h (Fig. 5). The Kd for binding of 3H-anti-Tac to 
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FIGURE 5. Time course of 1L-2 induction of Tac antigen expression on 5B4 cells. Specific 
binding of SH-anti-Tac is plotted as a function of the time of JURKAT IL-2 induction of 5B4 
cells cultured with 50 ng/ml purified IL-2. 
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FIGURE 6. IL-2 induction of 5B4 cells increases the binding of 3H-anti-Tac. Uninduced 5B4 
line bound 0.13 ng of 3H-anti-Tac/106 cells, indicating an average of 520 receptors per cell 
whereas 5B4 cells incubated with 50 ng of purified JURKAT IL-2 for 48 h bound 1.12 ng of 
anti-Tac/I 06 cells indicating an average of 4,500 receptors per cell with an apparent Kd of 
1.14 × 10 -1° M. 
the induced cell population was 1.14 x 10 -]° M (Fig. 6). The addition of 
cycloheximide (5 x 10 -6 M) abrogated the increase in IL-2 receptors after 
exposure to purified IL-2. The concentration fcycloheximide used blocked aH- 
leucine incorporation by 90%, but did not produce immediate cell death as 
assessed by trypan blue dye exclusion. Furthermore, actinomycin D (3 X 10 -7 M 
and 3 x 10 -8 M) produced >95% inhibition of IL-2 receptor induction. In 
contrast, inhibition of DNA synthesis by irradiation (2,000, 4,000, and 8,000 
tad) sufficient o inhibit thymidine uptake by 85% did not inhibit the IL-2- 
induced IL-2 receptor expression. With the 4,000 rad dose of irradiation, there 
was only a modest reduction in cell viability, with 91% of the cells still excluding 
trypan blue. Thus, the induction of IL-2 receptor expression after exposure of 
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FIGURE 7. Size of IL-2 receptors on cloned normal B cell lines 1C9 and 5B4. (A) 1C9 cells 
were biosynthetically labeled with [SH]n-glucosamine for 18 h solubilized in non-ionic deter- 
gent and immunoprecipitated with anti-Tac (lane A) or control UPC-10 antibody (lane B) as 
previously described (15). Immunoprecipitates were analyzed by SDS-PAGE on 8.75% gels 
performed under educing conditions. Migration of known molecular weight markers i shown. 
(B) The 5B4 cell line and activated T cells were surface iodinated and analyzed as in A. No 
radiolabeled proteins were precipitated by UPC-10 from uninduced (lane A) or induced (lane 
B) 5B4 cells. Anti-Tac immunoprecipitated a faint band from uninduced 5B4 cells (lane C) 
and a much more intense band from 5B4 cells induced for 48 h with 50 ng/ml of JURKAT 
IL-2 (lane D). Anti-Tac immunoprecipitation of surface-labeled, PHA-activated T lymphoblasts 
is shown in lane E. 
the 5B4 line to IL-2 requires RNA transcript ion and protein synthesis but not 
DNA replication. 
Structure oflL-2 Receptors on B Cells. On the basis o f  our  previous studies (15, 
31), the Tac ant igen (IL-2 receptor)  present on activated normal  T cells was 
shown to be a g lycoprotein with an Mr o f  53 ,000-57 ,000 .  The  Tac  ant igen on 
cloned normal  B cell line 1C9, biosynthetically labeled with [3H]~glucosamine 
and immunoprec ip i tated with ant i -Tac but not control  UPC-10 antibody, was 
similar in size to the receptor  on T cells (Fig. 7A). In addit ion, the size o f  the 
Tac ant igen on 5B4 cells induced with IL-2 and labeled with 1~5I was similar in 
size to the receptor  precipitated by ant i -Tac on simultaneously studied PHA-  
st imulated T cell iymphoblasts (Fig. 7B). 
Functional Effects of lL-2 and Anti-Tac on the B Cell Line 5B4. The synthesis 
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TABLE II 
The Effect of Purified JURKAT IL-2 and Anti-Tac on 
lramunoglobulin Synthesis by Line 5B4 
Growth factor added 
Immunoglobulin 
Monoclonal ntibody synthesized by 
10 6 5B4 cells in added culture 
for 14d 
ng 
1. None None 2,790 
2. IL-2 (100 ng) None 10,754 
3. IL-2 (20 ng) None 9,323 
4. None Anti-Tac (20 #g) 3,629 
5. None RPC-5 (20 #g) 3,842 
6. IL-2 (20 ng) Anti-Tac (20 ~g) 3,015 
7. IL-2 (20 ng) RPC-5 (20 ~g) 7,137 
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and secretion of IgM into the media in these cultures was increased two- to 
fourfold by the addition of 1, 10, 20, 50, or 100 ng of purif iedJURKAT IL-2/ 
10 6 5B4 cells per milliliter ml in culture (Table II). This IL-2-inducible compo- 
nent of IgM synthesis was completely blocked by the addition of 20 #g of anti- 
Tac. In contrast, the addition of the control monoclonal (RPC-5) did not alter 
I L-2-stimulated immunoglobulin synthesis. Furthermore, the addition of various 
concentrations of purified JURKAT IL-2 or anti-Tac had no effect on the cell 
number at the termination of the culture or the proliferation ([3H]thymidine 
uptake) of 5B4 cells, either when added before or after induction of IL-2 receptor 
expression (data not shown). Thus, IL-2 did not alter the rate of proliferation of 
the 5B4 line, but appeared to facilitate the terminal differentiation of these 
cloned normal B cells into immunoglobulin-synthesizing and -secreting cells. 
Discussion 
IL-2 Receptor Expression on Activated B Cells. In previous reports (4, 12), no 
receptors for IL-2 were demonstrated on resting B cells or on the activated B
cells examined. These activated B cells include LPS-stimulated mouse spleen 
cells as well as the Burkitt lines Raji and Daudi. In this report, we demonstrate 
that some activated B cells express membrane receptors for IL-2. Monoclonal 
anti-Tac, which identifies the human receptor for IL-2, binds to certain malignant 
B cell populations including 6 of 10 patients with Burkitt's lymphoma, and the 
B cell lines derived from 5 of 6 patients with the HTLV-I-associated adult T cell 
leukemia. Furthermore, B cells from normal individuals activated by PWM in 
the presence of T cells expressed the Tac antigen. In addition, cloned EBV- 
transformed B cell lines derived from Tac-positive activated normal B cells 
continued to express Tac antigen in long-term cultures. The binding of anti-Tac 
to B cells rather than T cells in each of these systems was confirmed by 
demonstrating that the purified cells and cell lines examined id not react with 
Leu-4 and that the Tac-positive cells assessed by two-color fluorescence analysis 
concomitantly expressed the B cell-associated antigen identified by the monocio- 
nal antibody Leu-10. Furthermore, both immunoaffinity-purified, JURKAT- 
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derived IL-2 and recombinant IL-2 blocked the binding of anti-Tac to the Tac- 
positive B cell lines. In addition, -1,400 high affinity IL-2 receptors were 
detectable on 1C9 cells when studied with purified radiolabeled IL-2. Finally, 
the size of the receptor identified by anti-Tac on B cells was similar to that 
present on activated T cells. These data are in accord with the view that some 
activated B cells express membrane receptors for IL-2. 
There are possible explanations for the discordance between this conclusion 
and the view expressed in previous tudies that B cells do not bear IL-2 receptors. 
We have shown that the Burkitt's lymphoma line studied previously, the Daudi 
line (12), which was reported to be IL-2 receptor negative, is also unreactive 
with anti-Tac. Furthermore, the level of Tac antigen expression on activated B
cells is 5-10-fold less than that characteristic of activated T cells (33). Even the 
Tac-positive B cell lines, 1 C9 and induced 5B4, which have the most receptors 
we have observed on normal B cells, manifested only 7,500 and 4,500 Tac 
receptors, respectively, as assessed by Scatchard analysis of 3H-anti-Tac binding, 
whereas PHA-activated T cells expressed 30,000-60,000 receptors per cell, and 
HTLV-positive adult T cell leukemia T cell lines such as HUT102 expressed 
150,000-600,000 Tac receptors per cell (33). Thus, the number of high affinity 
IL-2 receptors on the activated B cells studied previously may have been too low 
to be detected by some of the techniques used. Taken as a whole, the data 
support the hypothesis that IL-2 receptors are induced on some but not all 
activated B cell populations. 
IL-2 Induction of IL-2 Receptors on B Cells. The line 5B4 reported in the 
present study can be induced with IL-2 to express augmented numbers of 
receptors identified by the anti-Tac antibody (an increase from 520 to 4,500 
receptors per cell). These studies uggest hat IL-2 may up-regulate the number 
of IL-2 receptors expressed by this B cell line. The fact that both immunopurified 
JURKAT IL-2 and recombinant IL-2 could augment receptor expression sug- 
gests that IL-2 itself rather than any potential contaminant was the active agent. 
The requirements for RNA transcription and protein synthesis uggests that de 
novo receptor synthesis i  occurring rather than the unmasking of cryptic recep- 
tors. The view that IL-2 induces cells with low numbers of receptors to synthesize 
and express high numbers of cell surface IL-2 receptors rather than causing the 
outgrowth of cells with high numbers of receptors is supported by the observa- 
tions that the Tac receptors were induced within 12-24 h and that this induction 
was not inhibited by doses of gamma irradiation that profoundly inhibited DNA 
synthesis. Although in many receptor-ligand systems the addition of the ligand 
leads to down-regulation of the receptor numbers, there is precedence for up- 
regulation of the number of surface receptors by certain ligands. For example, 
surface Fc epsiion receptors were induced on activated T cells after the addition 
of IgE (34). Similarly, Fc alpha receptors were induced on T lymphocytes by 
addition of IgA to in vitro cultures of these cells (35). Furthermore, an increase 
in the number of insulin receptors was observed with 3T3 (36) and chondrosar- 
coma cell lines (37) in response to insulin. In 3T3 cells this induction was slow 
and was paralleled by the maturation of the 3T3 cells into more mature 
adipocytes (36). In the case of the chondrosarcoma cells there was no change in 
apparent state of maturation or phenotype of the cells (37). With the present 
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line, 5B4, there was no change in the proportion of cells that reacted with a 
series of monoclonal antibodies including B1, B2, T9, and BA1. Since the line 
5B4 is an EBV-transformed line that does not require exogenous IL-2 for its 
proliferation, it provides a valuable line for the study of the factors involved in 
the induction of IL-2 receptors on B lymphocytes. 
Functional Role of lL-2 in B Cell Differentiation. Although it appears that IL- 
2 receptors develop on certain B cells during their activation, the functional 
significance of the interaction of IL-2 with this receptor isnot clear. It is evident, 
for example, in studies of Tac-negative, EBV-transformed B cell lines that this 
interaction is not absolutely required for immunoglobulin synthesis, nor is the 
addition of IL-2 alone to B cells sufficient for B cell proliferation or differentia- 
tion. Furthermore, it is conceivable that the IL-2 binding receptors on B cells 
that we have identified might also be receptors for another B cell growth or 
differentiation factor. However, the high affinity (Kd, 2.7 X 10 -LI M) of the 
binding of IL-2 to these receptors on B cells would be more in line with primary 
specificity for IL-2 rather than for some other ligand. 
Anti-Tac inhibited polyclonal immunoglobulin biosynthesis in response to the 
helper T cell-dependent polyclonal activators, PWM, SLO, NWSM, and WGA. 
However, in these cases, the effect could either be on the B cells directly or on 
the production of B cell growth and differentiation factors by T cells. Howard 
and co-workers (38) have indeed demonstrated the requirement for IL-2 for the 
synthesis of B cell growth factor by T cells. However, IL-2 may have a more 
direct effect on B cells as well. In additional studies we have shown that the 
immunoglobulin biosynthesis response of rigorously T cell-depleted B cells to a 
crude T cell-replacing factor (the supernatants of T cells stimulated by PWM) 
was abrogated by the addition of 20 vg of anti-Tac. The B cells utilized in this 
latter study were prepared by adherence to anti-immunoglobulin columns fol- 
lowed by removal of any residual T cells by rosetting with neuraminidase-treated 
sheep erythrocytes and did not proliferate to T cell-mitogens. Furthermore, they 
did not synthesize immunoglobulins when stimulated with PWM. However, these 
B cells synthesized IgM, IgG, and IgA when cultured with the supernatants of T 
cells cultured for 48 h with PWM. This TRF-stimulated synthesis was abrogated 
when 20 ~g of anti-Tac was added. 
To avoid any potential effects of anti-Tac on such contaminating T cells that 
might be present in any preparation of freshly obtained mononuclear cells, we 
have also studied the effect of anti-Tac on immunoglobulin synthesis by a cloned 
B cell line from a normal individual, line 5B4. Immunoglobulin synthesis by this 
line was increased two- to fourfold by the addition of purified IL-2 in the absence 
of a concomitant increase in cell number. This increase in immunoglobulin 
synthesis could be completely blocked by the addition of anti-Tac (Table II). 
Augmentation of immunoglobulin synthesis in conjunction with the observation 
that neither IL-2 nor anti-Tac affected DNA replication by these B cells suggests 
that IL-2 can facilitate the terminal differentiation of B cells. Clearly, further 
studies are required to address the significance of the role of IL-2 in B cell 
proliferation and differentiation. However, these observations, taken in conjunc- 
tion with studies summarized by Howard and Paul (9), would support the 
following model of B cell activation, growth, and differentiation: B cells are 
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activated by the binding of appropriately presented antigen to its specific recep- 
tor, cell surface immunoglobulin. B cell activation progresses and the B cells 
enter a proliferative cycle after the interaction of IL-1 and BCGF with receptors 
for these ligands that appear on the B cell surface. The terminal maturation of 
these proliferating B cells involves the binding of a series of antigen-nonspecific 
B cell differentiation factors and, in certain cases, IL-2 with specific receptors 
inducibly expressed on the activated proliferating cells. Thus, IL-2 would join 
other antigen-nonspecific actors produced by T cells as a potential regulator of 
the differentiation of B cells into immunoglobulin-synthesizing a d -secreting 
cells. 
Summary 
Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we 
have explored the possibility that certain activated B cells display receptors for 
IL-2. Resting normal B cells and unselected B cell lines established from normal 
individuals were Tac antigen negative. In contrast, the cell surface Tac antigen 
expression was demonstrable on 6 of 10 B cell lines from patients with Burkitt's 
lymphoma, 5 of 6 B cell lines derived from patients with HTLV-I-associated 
adult T cell leukemia (including all four that had integrated HTLV-I into their 
genome), and on certain normal B cells activated with pokeweed mitogen. 
Furthermore, cloned Epstein-Barr virus-transformed B cell lines derived from 
Tac-positive normal B cells continued to express the Tac antigen in long-term 
cultures and manifested high affinity IL-2 receptors identified in binding studies 
with purified radiolabeled IL-2. The line 5B4 developed in the present study 
could be induced with purifiedJURKAT-derived or recombinant IL-2 to express 
a larger number of IL-2 receptors. Furthermore, the addition of IL-2 to the 5B4 
B cell line augmented IgM synthesis, which could be blocked by the addition of 
anti-Tac. The size of the IL-2 receptors expressed on the cloned normal B cell 
lines was similar (53,000-57,000 daltons) to that of receptors on phytohemag- 
glutinin-stimulated T cell lymphoblasts. Thus, certain malignant and activated 
normal B cells display the Tac antigen and manifest high affinity receptors for 
IL-2. These data suggest hat IL-2 may play a role in the differentiation of 
activated B cells into immunoglobulin-synthesizing a d -secreting cells. 
We express our thanks to David Stephany for performing many of the flow microfluoro- 
metry experiments. 
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